{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:15:31Z","timestamp":1790972131054,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Science and Technology Bureau, Jiangning District, Nanjing","award":["2020SHSY0119"],"award-info":[{"award-number":["2020SHSY0119"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10620-021-07042-x","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T19:03:07Z","timestamp":1622055787000},"page":"872-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Downregulation of Serum and Distal Ileum Fibroblast Growth Factor19 in Bile Acid Diarrhoea Patients"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-4042","authenticated-orcid":false,"given":"Chunxia","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenggen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-4839","authenticated-orcid":false,"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"7042_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/MEG.0000000000000541","volume":"28","author":"S Lin","year":"2016","unstructured":"Lin S, Sanders DS, Gleeson JT, et al. Long-term outcomes inpatients diagnosed with bile-acid diarrhea. Eur J Gastroenterol Hepatol. 2016;28:240\u2013245.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"7042_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1365-2982.2012.01953.x","volume":"24","author":"DJ Gracie","year":"2012","unstructured":"Gracie DJ, Kane JS, Mumtaz S, et al. Prevalence of, and pre-dictors of bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil. 2012;24:983-e538.","journal-title":"Neurogastroenterol Motil."},{"key":"7042_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1365-2036.2009.04081.x","volume":"30","author":"L Wedlake","year":"2009","unstructured":"Wedlake L, A\u2019hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30:707\u2013717.","journal-title":"Aliment Pharmacol Ther."},{"key":"7042_CR4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/gutjnl-2017-315909","volume":"67","author":"RP Arasaradnam","year":"2018","unstructured":"Arasaradnam RP, Brown S, Forbes A et al. Guidelines for the investigation of chronic diarrhea in adults: British Society of Gastroenterology, 3rd edition. Gut 2018;67:1380\u20131399.","journal-title":"Gut"},{"key":"7042_CR5","unstructured":"Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of Gastroenterology, et al. Guideline for primary care of chronic diarrhea (2019). Chin J Gen Pract. 2020;19: 973\u2013982."},{"key":"7042_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.424","volume":"111","author":"IM Johnston","year":"2016","unstructured":"Johnston IM, Nolan JD, Pattni SS et al. Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary bile acid diarrhea. Am J Gastroenterol. 2016;111:423\u2013432.","journal-title":"Am J Gastroenterol."},{"issue":"8","key":"7042_CR7","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/apt.13570","volume":"43","author":"N Mottacki","year":"2016","unstructured":"Mottacki N, Simren M, Baior A. Review article: bile acid diarrhea pathogenesis, diagnosis and management. Aliment Pharmacol Ther. 2016;43:884\u2013898.","journal-title":"Aliment Pharmacol Ther."},{"key":"7042_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0300-5089(21)00739-2","volume":"15","author":"H Fromm","year":"1986","unstructured":"Fromm H, Malavolti M. Bile acid-induced diarrhoea. Clin Gastroenterol. 1986;15:567\u2013582.","journal-title":"Clin Gastroenterol."},{"key":"7042_CR9","doi-asserted-by":"publisher","first-page":"e13666","DOI":"10.1111\/nmo.13666","volume":"31","author":"SJ Lim","year":"2019","unstructured":"Lim SJ, Gracie DJ, Kane JS et al. Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: a follow-up study. Neurogastroenterol Motil. 2019;31:e13666.","journal-title":"Neurogastroenterol Motil."},{"key":"7042_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/flgastro-2018-101011","volume":"10","author":"DCR Fernandes","year":"2019","unstructured":"Fernandes DCR, Poon D, White LL, Andreyev HJ. What is the cost of delayed diagnosis of bile acid malabsorption and bile acid diarrhoea? Frontline Gastroenterol. 2019;10:72\u201376.","journal-title":"Frontline Gastroenterol."},{"key":"7042_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cgh.2019.08.062","volume":"18","author":"DC Sadowski","year":"2020","unstructured":"Sadowski DC, Camilleri M, Chey WD et al. Canadian association of gastroenterology clinical practice guideline on the management of the bile acid diarrhea. Clin Gastroenterol Hepatol. 2020;18:24-41.e1.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7042_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/apt.14214","volume":"46","author":"P Vijayvargiya","year":"2017","unstructured":"Vijayvargiya P, Camilleri M, Carlson P et al. Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhea in IBS-diarrhea and functional diarrhea. Aliment Pharmacol Ther. 2017;46:581\u2013588.","journal-title":"Aliment Pharmacol Ther."},{"key":"7042_CR13","first-page":"171","volume":"1546","author":"GP Palace","year":"2001","unstructured":"Palace GP, Lazari P, Norton K. Analysis of the physicochemical interactions between Clostridium difficiletoxins and cholestyramine using liquid chromatograph with post-column derivatization. Biochem Biophys Acta 2001;1546:171\u2013184.","journal-title":"Biochem Biophys Acta"},{"key":"7042_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12876-019-1102-1","volume":"19","author":"I Lyutakov","year":"2019","unstructured":"Lyutakov I, Ursini F, Penchev P et al. Methods for diagnosing bile acid malabsorption: a systematic review. BMC Gastroenterol 2019;19:185\u2013185.","journal-title":"BMC Gastroenterol"},{"key":"7042_CR15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/nmo.12421","volume":"26","author":"M Camilleri","year":"2014","unstructured":"Camilleri M, Shin A, Busciglio I et al. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neuro Gastroenterol Motil. 2014;26:1677\u20131685.","journal-title":"Neuro Gastroenterol Motil."},{"key":"7042_CR16","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.cgh.2013.04.020","volume":"11","author":"A Shin","year":"2013","unstructured":"Shin A, Camilleri M, Vijayvargiya P et al. Bowelfunctions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:1270-1275.e1.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7042_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1006\/cyto.1999.0485","volume":"11","author":"MH Xie","year":"1999","unstructured":"Xie MH, Holcomb I, Deuel B et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11:729\u2013735.","journal-title":"Cytokine"},{"key":"7042_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/hep.26402","volume":"58","author":"K Wang","year":"2013","unstructured":"Wang K, Lim HY, Shi S et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 2013;58:706\u2013717.","journal-title":"Hepatology"},{"key":"7042_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1055\/a-0623-2909","volume":"50","author":"N Babaknejad","year":"2018","unstructured":"Babaknejad N, Nayeri H, Hemmati R, Bahrami S, Esmaillzadeh A. An overview of FGF19 and FGF21: the therapeutic role in the treatment of the metabolic disorders and obesity. Horm Metab Res. 2018;50:441\u2013452.","journal-title":"Horm Metab Res."},{"key":"7042_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","volume":"15","author":"C Degirolamo","year":"2016","unstructured":"Degirolamo C, Sabb\u00e0 C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factorsFGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15:51\u201369.","journal-title":"Nat Rev Drug Discov."},{"key":"7042_CR21","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim RD, Sarker D, Meyer T et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9:1696\u20131707.","journal-title":"Cancer Discov."},{"key":"7042_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000494454","volume":"37","author":"D Wang","year":"2019","unstructured":"Wang D, Zhang J, Li Z et al. Upregulation of fibroblast growth factor 19 is associated with the initiation of colorectal adenoma. Dig Dis Sci. 2019;37:214\u2013225.","journal-title":"Dig Dis Sci."},{"key":"7042_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0016-5085(08)61895-8","volume":"134","author":"AM Tasleem","year":"2008","unstructured":"Tasleem AM, Dew T, Balesaria S, et al. M1725 reduced serum fibroblast growth factor 19 (FGF19) in patients with idiopathic bile acid malabsorption. Gastroenterology. 2008;134:405\u2013406.","journal-title":"Gastroenterology."},{"key":"7042_CR24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cgh.2009.04.024","volume":"7","author":"JR Walters","year":"2009","unstructured":"Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea:defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009;7:1189\u20131194.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"7042_CR25","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.cgh.2012.05.006","volume":"10","author":"BS Wong","year":"2012","unstructured":"Wong BS, Camilleri M, Carlson P et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin gastroenterol Hepatol 2012;10:1009-1015.e3. https:\/\/doi.org\/10.1016\/j.cgh.2012.05.006.","journal-title":"Clin gastroenterol Hepatol"},{"key":"7042_CR26","unstructured":"Digestive Endoscopy Special Committee of Endoscopic Physicians Branch of Chinese Medical Association, Cancer Endoscopy Committee of China Anti-Cancer Association. Chinese guideline for bowel preparation for colonscopy (2019, Shanghai). Chine J Inter Med. 2019;58: 485\u2013495."},{"key":"7042_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJM196908212810801","volume":"281","author":"AF Hofmann","year":"1969","unstructured":"Hofmann AF, Poley JR. Cholestyramine treatment diarrhea associated with ileal resection. N Engl J Med. 1969;281:397\u2013402.","journal-title":"N Engl J Med."},{"key":"7042_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1665-2681(19)30766-5","volume":"14","author":"F Barrera","year":"2015","unstructured":"Barrera F, Azocar L, Molina H et al. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Ann Hepatol. 2015;14:710\u2013721.","journal-title":"Ann Hepatol."},{"key":"7042_CR29","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.14309\/ajg.0000000000000772","volume":"115","author":"C Broup","year":"2020","unstructured":"Broup C, Wildt S, Rumessen J et al. Biochemical diagnosis of bile acid diarrhea prospective comparison with the 75seleno-taurohomocholic acid test. Am J Gastroenterol. 2020;115:2086\u20132094.","journal-title":"Am J Gastroenterol."},{"key":"7042_CR30","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.cgh.2018.11.012","volume":"17","author":"R Battat","year":"2019","unstructured":"Battat R, Duijvestein M, Casteele NV et al. Serum concentrations of 7\u03b1-hydroxy-4-cholesten-3-one are associated with bile acid diarrhea in patients with Cronh\u2019s disease. Clin Gastroenterol Hepatol. 2019;17:2722-2730.e4.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7042_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/apt.12466","volume":"38","author":"SS Pattni","year":"2013","unstructured":"Pattni SS, Brydon WG, Dew T et al. Fibroblast growth factor 19 in patients with bile acid diarrhea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther. 2013;38:967\u2013976.","journal-title":"Aliment Pharmacol Ther."},{"key":"7042_CR32","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1136\/gutjnl-2015-309889","volume":"65","author":"N Valentin","year":"2016","unstructured":"Valentin N, Canilleri M, Altayar O et al. Biomakers for bile acid diarrhea in functional bowel disorder with diarrhea: a systematic review and meta-analysis. Gut. 2016;65:1951\u20131959.","journal-title":"Gut."},{"key":"7042_CR33","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1038\/ctg.2012.10","volume":"3","author":"SS Pattni","year":"2012","unstructured":"Pattni SS, Brydon WG, Dew T et al. Fibroblast growth factor 19 and 7\u03b1-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin Transl Gastroenterol. 2012;3:e18.","journal-title":"Clin Transl Gastroenterol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-021-07042-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T18:44:50Z","timestamp":1648233890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-021-07042-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["7042"],"URL":"https:\/\/doi.org\/10.1007\/s10620-021-07042-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"7 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional Research Ethics Committee of Nanjing Tongren Hospital(Protocol numbers: TRLLKY2020001.1 Protocol title: The diagnostic value of serum FGF19 for bile acid diarrhoea).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}